Laurie Norton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Laurie Norton has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Jingsan Zhu
University of Pennsylvania
4 shared publications- Alexander C. Fanaroff
Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA; Leonard Davis Institute for Health Economics, University of Pennsylvania, Philadelphia, PA; Penn Center for Health Incentives and Behavioral Economics, University of Pennsylvania, Philadelphia, PA
3 shared publications - Charles Rareshide
University of Pennsylvania
3 shared publications - Mitesh S. Patel
Ascension Health, St. Louis, MO (M.S.P.).
3 shared publications - Neel P. Chokshi
University of Pennsylvania
3 shared publications Samantha Coratti
University of Pennsylvania
3 shared publications
Latest Publications
- Open Access
- 16 December 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (24) , e038921
Effect of Gamification Plus Automated Coaching to Increase Physical Activity Among Patients With Peripheral Artery Disease: The GAMEPAD Randomized Controlled Trial
Background: Supervised exercise therapy improves walking performance in patients with peripheral artery disease (PAD), but few participate. Interventions leveraging concepts from behavioral economics increase physical activity in patients at high cardiovascular risk, but barriers to physical activity differ in patients with PAD. Methods: In this randomized controlled trial, conducted from October 2020 through January 2024, patients with PAD were provided with a wearable fitness tracker, established a baseline daily step count, and set a step goal increase. They were randomly assigned to attention control or to gamification. The control group received feedback from the fitness tracker but no other interventions for 24 weeks. The gamification group was entered into a 16‐week game designed using insights from behavioral economics and received educational text messages. No intervention occurred during an 8‐week postintervention follow‐up period. Results: A total of 103 patients (mean age, 70±9 years; 54 [52%] men, 74 (72%) with exertional lower extremity symptoms) were randomized to attention control (n=52) or gamification (n=51). Compared with controls, gamification participants had a greater increase in mean daily steps from baseline during the intervention period (adjusted difference, 920 [95% CI, −22 to 1861]; P =0.06) that became statistically significant during the follow‐up period (adjusted difference, 1074 [95% CI, 133–2015]; P =0.03). Conclusions: In this randomized clinical trial, gamification increased physical activity compared with attention control over a 24‐week follow‐up. This intervention may represent a scalable approach for increasing physical activity in patients with PAD who are not able to participate in supervised exercise therapy. Registration: URL: https://clinicaltrials.gov/study/NCT04536012 ; Unique Identifier: NCT04536012.
- 16 December 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (24) , e038921
Open AccessEffect of Gamification Plus Automated Coaching to Increase Physical Activity Among Patients With Peripheral Artery Disease: The GAMEPAD Randomized Controlled Trial
Background: Supervised exercise therapy improves walking performance in patients with peripheral artery disease (PAD), but few participate. Interventions leveraging concepts from behavioral economics increase physical activity in patients at high cardiovascular risk, but barriers to physical activity differ in patients with PAD. Methods: In this randomized controlled trial, conducted from October 2020 through January 2024, patients with PAD were provided with a wearable fitness tracker, established a baseline daily step count, and set a step goal increase. They were randomly assigned to attention control or to gamification. The control group received feedback from the fitness tracker but no other interventions for 24 weeks. The gamification group was entered into a 16‐week game designed using insights from behavioral economics and received educational text messages. No intervention occurred during an 8‐week postintervention follow‐up period. Results: A total of 103 patients (mean age, 70±9 years; 54 [52%] men, 74 (72%) with exertional lower extremity symptoms) were randomized to attention control (n=52) or gamification (n=51). Compared with controls, gamification participants had a greater increase in mean daily steps from baseline during the intervention period (adjusted difference, 920 [95% CI, −22 to 1861]; P =0.06) that became statistically significant during the follow‐up period (adjusted difference, 1074 [95% CI, 133–2015]; P =0.03). Conclusions: In this randomized clinical trial, gamification increased physical activity compared with attention control over a 24‐week follow‐up. This intervention may represent a scalable approach for increasing physical activity in patients with PAD who are not able to participate in supervised exercise therapy. Registration: URL: https://clinicaltrials.gov/study/NCT04536012 ; Unique Identifier: NCT04536012.
- 1 July 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 18 (7) , e011839
Cost-Effectiveness of Gamification, Financial Incentives, or Both to Increase Physical Activity Among Patients With Elevated Risk for Cardiovascular Disease
BACKGROUND: The BE ACTIVE trial (Behavioral Economic Approaches to Increase Physical Activity Among Patients with Elevated Risk for Cardiovascular Disease) documented the effectiveness, compared with an attention control arm that received daily text messages, of gamification, financial incentives, or gamification+financial incentives to increase steps/day. Increases in daily step count are associated with longer life expectancy, but understanding the cost-effectiveness of these interventions is essential for payers and other stakeholders seeking to implement findings. METHODS: We built a probabilistic Markov model to compare intervention costs with lifetime estimates of life-years and quality-adjusted life-years for 2 sets of comparisons: (1) each behavioral intervention versus attention control, and (2) each trial arm, including attention control, versus no intervention. Since the durability of changes in steps/day post-intervention is unknown, we modeled optimistic, intermediate, and pessimistic scenarios. RESULTS: Over the 12-month intervention, per-participant cost to deliver attention control was $878, gamification $938, financial incentives $1534, and gamification+financial incentives $1712. Compared with attention control, gamification’s cost-effectiveness ranged from $261 (95% CI, 259–263) per life-year gained if mean steps/day during the last 18 weeks of follow-up are maintained (optimistic), to $30 550 (95% CI, 30 503–30 597) per life-year if steps/day continue to decline at the rate observed during the full 26-week follow-up (pessimistic). Gamification+financial incentives cost <$50 000/life-year only under the optimistic and intermediate scenarios. Financial incentives was dominated by gamification and gamification+financial incentives. When all 4 trial arms, including attention control, were compared with no intervention, gamification again cost <$50 000/life-year across all durability scenarios. CONCLUSIONS: Across a range of scenarios about the durability of increases in steps/day post-intervention, gamification consistently cost <$50 000 per life-year gained, the threshold for high value interventions set by American College of Cardiology/American Heart Association guidelines. Gamification+financial incentives was high-value except in the pessimistic scenario. Financial incentives was dominated. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03911141.
- 1 July 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 18 (7) , e011839
Cost-Effectiveness of Gamification, Financial Incentives, or Both to Increase Physical Activity Among Patients With Elevated Risk for Cardiovascular Disease
BACKGROUND: The BE ACTIVE trial (Behavioral Economic Approaches to Increase Physical Activity Among Patients with Elevated Risk for Cardiovascular Disease) documented the effectiveness, compared with an attention control arm that received daily text messages, of gamification, financial incentives, or gamification+financial incentives to increase steps/day. Increases in daily step count are associated with longer life expectancy, but understanding the cost-effectiveness of these interventions is essential for payers and other stakeholders seeking to implement findings. METHODS: We built a probabilistic Markov model to compare intervention costs with lifetime estimates of life-years and quality-adjusted life-years for 2 sets of comparisons: (1) each behavioral intervention versus attention control, and (2) each trial arm, including attention control, versus no intervention. Since the durability of changes in steps/day post-intervention is unknown, we modeled optimistic, intermediate, and pessimistic scenarios. RESULTS: Over the 12-month intervention, per-participant cost to deliver attention control was $878, gamification $938, financial incentives $1534, and gamification+financial incentives $1712. Compared with attention control, gamification’s cost-effectiveness ranged from $261 (95% CI, 259–263) per life-year gained if mean steps/day during the last 18 weeks of follow-up are maintained (optimistic), to $30 550 (95% CI, 30 503–30 597) per life-year if steps/day continue to decline at the rate observed during the full 26-week follow-up (pessimistic). Gamification+financial incentives cost <$50 000/life-year only under the optimistic and intermediate scenarios. Financial incentives was dominated by gamification and gamification+financial incentives. When all 4 trial arms, including attention control, were compared with no intervention, gamification again cost <$50 000/life-year across all durability scenarios. CONCLUSIONS: Across a range of scenarios about the durability of increases in steps/day post-intervention, gamification consistently cost <$50 000 per life-year gained, the threshold for high value interventions set by American College of Cardiology/American Heart Association guidelines. Gamification+financial incentives was high-value except in the pessimistic scenario. Financial incentives was dominated. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03911141.
- Top Cited Papers
- 21 May 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 149 (21) , 1639-1649
Effect of Gamification, Financial Incentives, or Both to Increase Physical Activity Among Patients at High Risk of Cardiovascular Events: The BE ACTIVE Randomized Controlled Trial
BACKGROUND: Physical activity is associated with a lower risk of major adverse cardiovascular events, but few individuals achieve guideline-recommended levels of physical activity. Strategies informed by behavioral economics increase physical activity, but their longer-term effectiveness is uncertain. We sought to determine the effect of behaviorally designed gamification, loss-framed financial incentives, or their combination on physical activity compared with attention control over 12-month intervention and 6-month postintervention follow-up periods. METHODS: Between May 2019 and January 2024, participants with clinical atherosclerotic cardiovascular disease or a 10-year risk of myocardial infarction, stroke, or cardiovascular death of ≥7.5% by the Pooled Cohort equation were enrolled in a pragmatic randomized clinical trial. Participants received a wearable device to track daily steps, established a baseline, selected a step goal increase, and were randomly assigned to control (n=151), behaviorally designed gamification (n=304), loss-framed financial incentives (n=302), or gamification+financial incentives (n=305). The primary outcome of the trial was the change in mean daily steps from baseline through the 12-month intervention period. RESULTS: A total of 1062 patients (mean±SD age, 67±8; 61% female; 31% non-White) were enrolled. Compared with control subjects, participants had significantly greater increases in mean daily steps from baseline during the 12-month intervention in the gamification arm (adjusted difference, 538.0 [95% CI, 186.2–889.9]; P =0.0027), financial incentives arm (adjusted difference, 491.8 [95% CI, 139.6–844.1]; P =0.0062), and gamification+financial incentives arm (adjusted difference, 868.0 [95% CI, 516.3–1219.7]; P P =0.0028), but it was not significantly greater in the gamification (adjusted difference, 459.8 [95% CI, 82.0–837.6]; P =0.0171) or financial incentives (adjusted difference, 327.9 [95% CI, −50.2 to 706]; P =0.09) arms after adjustment for multiple comparisons. CONCLUSIONS: Behaviorally designed gamification, loss-framed financial incentives, and the combination of both increased physical activity compared with control over a 12-month intervention period, with the largest effect in gamification+financial incentives. These interventions could be a useful component of strategies to reduce cardiovascular risk in high-risk patients. REGISTRATION: URL: https://clinicaltrials.gov ; Unique Identifier: NCT03911141.
- 21 May 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 149 (21) , 1639-1649
Top Cited PapersEffect of Gamification, Financial Incentives, or Both to Increase Physical Activity Among Patients at High Risk of Cardiovascular Events: The BE ACTIVE Randomized Controlled Trial
BACKGROUND: Physical activity is associated with a lower risk of major adverse cardiovascular events, but few individuals achieve guideline-recommended levels of physical activity. Strategies informed by behavioral economics increase physical activity, but their longer-term effectiveness is uncertain. We sought to determine the effect of behaviorally designed gamification, loss-framed financial incentives, or their combination on physical activity compared with attention control over 12-month intervention and 6-month postintervention follow-up periods. METHODS: Between May 2019 and January 2024, participants with clinical atherosclerotic cardiovascular disease or a 10-year risk of myocardial infarction, stroke, or cardiovascular death of ≥7.5% by the Pooled Cohort equation were enrolled in a pragmatic randomized clinical trial. Participants received a wearable device to track daily steps, established a baseline, selected a step goal increase, and were randomly assigned to control (n=151), behaviorally designed gamification (n=304), loss-framed financial incentives (n=302), or gamification+financial incentives (n=305). The primary outcome of the trial was the change in mean daily steps from baseline through the 12-month intervention period. RESULTS: A total of 1062 patients (mean±SD age, 67±8; 61% female; 31% non-White) were enrolled. Compared with control subjects, participants had significantly greater increases in mean daily steps from baseline during the 12-month intervention in the gamification arm (adjusted difference, 538.0 [95% CI, 186.2–889.9]; P =0.0027), financial incentives arm (adjusted difference, 491.8 [95% CI, 139.6–844.1]; P =0.0062), and gamification+financial incentives arm (adjusted difference, 868.0 [95% CI, 516.3–1219.7]; P P =0.0028), but it was not significantly greater in the gamification (adjusted difference, 459.8 [95% CI, 82.0–837.6]; P =0.0171) or financial incentives (adjusted difference, 327.9 [95% CI, −50.2 to 706]; P =0.09) arms after adjustment for multiple comparisons. CONCLUSIONS: Behaviorally designed gamification, loss-framed financial incentives, and the combination of both increased physical activity compared with control over a 12-month intervention period, with the largest effect in gamification+financial incentives. These interventions could be a useful component of strategies to reduce cardiovascular risk in high-risk patients. REGISTRATION: URL: https://clinicaltrials.gov ; Unique Identifier: NCT03911141.
- Open Access
- 12 January 2022
- Published by SAGE Publications in Medical Decision Making
- Vol. 42 (8) , 975-984
The Electronic Health Record as the Primary Data Source in a Pragmatic Trial: A Case Study
Introduction. Pragmatic clinical trials test interventions in patients representative of real-world medical practice and reduce data collection costs by using data recorded in the electronic health record (EHR) during usual care. We describe our experience using the EHR to measure the primary outcome of a pragmatic trial, hospital readmissions, and important clinical covariates. Methods. The trial enrolled patients recently discharged from the hospital for treatment of heart failure to test whether automated daily monitoring integrated into the EHR could reduce readmissions. The study team used data from the EHR and several data systems that drew on the EHR, supplemented by the hospital admissions files of three states. Results. Almost three-quarters of enrollees’ readmissions over the 12-mo trial period were captured by the EHRs of the study hospitals. State data, which took 7 mo to more than 2 y from first contact to receipt of first data, provided the remaining one-quarter. Considerable expertise was required to resolve differences between the 2 data sources. Common covariates used in trial analyses, such as weight and body mass index during the index hospital stay, were available for >97% of enrollees from the EHR. Ejection fraction, obtained from echocardiograms, was available for only 47.6% of enrollees within the 6-mo window that would likely be expected in a traditional trial. Discussion. In this trial, patient characteristics and outcomes were collected from existing EHR systems, but, as usual for EHRs, they could not be standardized for date or method of measurement and required substantial time and expertise to collect and curate. Hospital admissions, the primary trial outcome, required additional effort to locate and use supplementary sources of data. Highlights: Electronic health records are not a single system but a series of overlapping and legacy systems that require time and expertise to use efficiently. Commonly measured patient characteristics such as weight and body mass index are relatively easy to locate for most trial enrollees but less common characteristics, like ejection fraction, are not. Acquiring essential supplementary data—in this trial, state data on hospital admission—can be a lengthy and difficult process.
- 12 January 2022
- Published by SAGE Publications in Medical Decision Making
- Vol. 42 (8) , 975-984
Open AccessThe Electronic Health Record as the Primary Data Source in a Pragmatic Trial: A Case Study
Introduction. Pragmatic clinical trials test interventions in patients representative of real-world medical practice and reduce data collection costs by using data recorded in the electronic health record (EHR) during usual care. We describe our experience using the EHR to measure the primary outcome of a pragmatic trial, hospital readmissions, and important clinical covariates. Methods. The trial enrolled patients recently discharged from the hospital for treatment of heart failure to test whether automated daily monitoring integrated into the EHR could reduce readmissions. The study team used data from the EHR and several data systems that drew on the EHR, supplemented by the hospital admissions files of three states. Results. Almost three-quarters of enrollees’ readmissions over the 12-mo trial period were captured by the EHRs of the study hospitals. State data, which took 7 mo to more than 2 y from first contact to receipt of first data, provided the remaining one-quarter. Considerable expertise was required to resolve differences between the 2 data sources. Common covariates used in trial analyses, such as weight and body mass index during the index hospital stay, were available for >97% of enrollees from the EHR. Ejection fraction, obtained from echocardiograms, was available for only 47.6% of enrollees within the 6-mo window that would likely be expected in a traditional trial. Discussion. In this trial, patient characteristics and outcomes were collected from existing EHR systems, but, as usual for EHRs, they could not be standardized for date or method of measurement and required substantial time and expertise to collect and curate. Hospital admissions, the primary trial outcome, required additional effort to locate and use supplementary sources of data. Highlights: Electronic health records are not a single system but a series of overlapping and legacy systems that require time and expertise to use efficiently. Commonly measured patient characteristics such as weight and body mass index are relatively easy to locate for most trial enrollees but less common characteristics, like ejection fraction, are not. Acquiring essential supplementary data—in this trial, state data on hospital admission—can be a lengthy and difficult process.